I would like to dedicate this episode to all the ROS developers out there who are considering a career in robotics. Are you worried about whether ROS is a valuable skill and if companies are actually looking for it? If so, this episode is for you! This podcast explores real data to give you a clear picture of ROS job opportunities. We'll cover: 1. …

I would like to dedicate this episode to all the ROS developers out there who are thinking and worrying about the future of ROS. If you are worried about whether ROS will become irrelevant in the future or if all the companies building humanoid robots will replace ROS, then this episode is dedicated to you!Before […] The post 130. The Open Source R…

I would like to dedicate this episode to all the ROS developers out there who are thinking and worrying about the future of ROS. If you are worried about whether ROS will become irrelevant in the future or if all the companies building humanoid robots will replace ROS, then this episode is dedicated to you! In this Podcast, we will delve into what …

I would like to dedicate this episode to all the ROS Developers who believe that ChatGPT or Compiler won't take our jobs but rather help us become more efficient and create better, faster, and more intelligent programs. If you share this perspective, this episode is dedicated to you! In this episode, we will dive into Generative AI tools for roboti…

I would like to dedicate this episode to all the ROS Developers who believe that ChatGPT or Compiler won’t take our jobs but rather help us become more efficient and create better, faster, and more intelligent programs. If you share this perspective, this episode is dedicated to you! In this episode, we will dive into Generative […] The post 129. r…

Roivant Pharma is reinventing the discovery, development, and commercialization of new medicines. Mayukh Sukhatme, M.D. was recently appointed to Roivant's board of directors and has served as Roivant’s President and Chief Investment Officer since January 2021. He is responsible for identifying, performing diligence on, devising development strateg…

Dr. Ignacio Guerrero-Ros is an immunologist turned scientific communicator and biotech media innovator. Currently, he is an Assistant Vice President at Russo Partners, providing public and investor relations services to clients in the healthcare and technology industries. Originally from Spain, Ignacio earned his PhD in Immunology from Albert Einst…

I would like to dedicate this episode to all the ROS developers who want to use large-scale realistic robotic simulations. If you are thinking of working in that direction, this podcast episode is dedicated to you! Today we are going to talk a lot about simulation and how to do it with open-source code. But […] The post 128. O3DE Robotics Simulator…

I would like to dedicate this episode to all the ROS developers who want to use large-scale realistic robotic simulations. If you are thinking of working in that direction, this podcast episode is dedicated to you! Today we are going to talk a lot about simulation and how to do it with open-source code. Now let me introduce you, Adam Dabrowski. Ada…

I would like to dedicate this episode to the people who are still working on autonomous driving. We believe that it will be the technology of the future, with many interesting and exciting job opportunities. We want to promote and support those who are actively involved in this field. So, if that describes you, this episode is dedicated to you! Tod…

I would like to dedicate this episode to the people who are still working on autonomous driving. We believe that it will be the technology of the future, with many interesting and exciting job opportunities. We want to promote and support those who are actively involved in this field. So, if that describes you, this […] The post 127. Autonomous Dri…

I would like to dedicate this episode to all the ROS developers who are considering professional robots and applications design, beginning with simulations. Starting with simulations is crucial, even if your preference is to work with real robots, to avoid errors and save time. If this is what you think when you are developing robots, […] The post …

I would like to dedicate this episode to all the ROS developers who are considering professional robots and applications design, beginning with simulations. Starting with simulations is crucial, even if your preference is to work with real robots, to avoid errors and save time. If this is what you think when you are developing robots, then this epi…

Carina Clingman, Ph.D., is the Founder and CEO of Recruitomics Consulting, a niche talent acquisition and talent strategy firm specializing in biotech startups. She recently founded The Collaboratory Career Hub to help biotech job seekers find confidence and success in their job search. If you're exploring careers in biotech, join the free Collabor…

About this episode: David Dornan is the Chief Scientific Officer of Elevation Oncology, a clinical-stage biotech company developing targeted cancer therapeutics, with a focus on antibody drug conjugates. David brings to Elevation over two decades of industry and academic oncology drug discovery and development experience. His research spans multipl…

I would like to dedicate this episode to all the ROS developers who are thinking about using ROS for their Drones or may be trying to apply their path planning to drones. If you are thinking about using your favorite robot framework for drones, then this episode is dedicated to you! Today, we will talk about Drones and ROS, delving into everything …

I would like to dedicate this episode to all the ROS developers who are thinking about using ROS for their Drones or may be trying to apply their path planning to drones. If you are thinking about using your favorite robot framework for drones, then this episode is dedicated to you! Today, we will talk […] The post 124. ROS for Drones appeared firs…

Points to touch: Is AI so dangerous? Will robots take our jobs? Can robots take the world? Can they save us from ourselves? Intro Terminator, the Matrix, I Robot, Ex Machina, all those movies indicate the danger that we may suffer in the future if we build robots with AI. But is the future going […] The post Robotics Insider EP3: What Will the Robo…

I would like to dedicate this episode to all the ROS developers who have already switched to ROS2 to control their robots. Today we are going to talk about the ros2_control with one of the main developers and maintainers of the packages. But before going into the meat, let me tell you about the […] The post 123. ROS2 Control Round 2 appeared first …

Emily Gransky is the Vice President of Recruiting at RA Ventures (RAVen). RAVen is the early-stage venture arm of the multi-stage investment firm RA Capital. In this role, Emily works closely with senior leaders, venture partners, and managing directors within the Venture Team at RA Capital and within RAVen. Her primary responsibility is leading an…

I would like to dedicate this episode to all the ROS developers who have already switched to ROS2 to control their robots. Today we are going to talk about the ros2_control with one of the main developers and maintainers of the packages. Now let’s go to the meat of the episode. Let me introduce you Dr. Denis Stogl. Denis is the CEO and founder of S…

Dr. Isaac Klein is the Chief Scientific Officer at Dewpoint Therapeutics. Dewpoint Therapeutics is leveraging condensate biology to impact a wide range of therapeutic targets across diverse disease areas. Armed with significant funding from venture capital and several big pharma partnerships, Dewpoint is poised to lead the generation of medicines t…

I would like to dedicate this episode to all the ROS developers that are considering building their own robotics startup. Today we are going to talk about this subject, how to build your robotics startup with a person that has already built two of them: one about hardware and another about software, and both of them are up and running. Now let’s go…

I would like to dedicate this episode to all the ROS developers that are considering building their own robotics startup. Today we are going to talk about this subject, how to build your robotics startup with a person that has already built two of them: one about hardware and another about software, and both […] The post 122. How to Build Robotics …

I would like to dedicate this episode to all the ROS developers in Asia that are struggling to get their industrial robots with ROS. Do not be desperate. Keep pushing your ROS learning and application. There are a lot of people working hard to help you with that, for instance, the guys from ROS Industrial Asia-Pacific. Now let’s go to the meat of t…

I would like to dedicate this episode to all the ROS developers in Asia that are struggling to get their industrial robots with ROS. Do not be desperate. Keep pushing your ROS learning and application. There are a lot of people working hard to help you with that, for instance, the guys from ROS Industrial […] The post 121. Developing robotics in Si…

Dr. Adam Jenkins is the Regional Site Director for the Massachusetts sites of Biolabs. BioLabs is an international, membership-based network of shared lab and office facilities located in key biotech innovation clusters. Since 2009, over 230 companies have launched from Biolabs facilities, and those member companies have collectively raised more th…

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s missio…

I would like to dedicate this episode to all the developers that are building and programming the robots that will go to space in the next missions. Now let’s go to the meat of the episode. Let me introduce you Will Chambers. Will was the principal technologist in AI and robotics at Blue Origin, where he cooperated to found the Space Robot Operatio…

I would like to dedicate this episode to all the developers that are struggling to set up complex networks of ROS2 devices. Now let’s go to the meat of the episode. Let me introduce you Julien Enoch. Julien is Senior Solutions Architect at ZettaScale Technology as well as Eclipse Zenoh committer. Today he is going to talk about what is Zenoh and wh…

Brian Culley is the CEO of Lineage Cell Therapeutics, a clinical-stage biotech company whose mission is to pioneer a new branch of medicine based on transplanting specific cell types to patients with serious medical conditions. Lineage currently has several programs undergoing clinical and preclinical investigation for indications in ophthalmology,…

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases. Alejandro Dorenbaum is the Chief Medical Officer of Reneo Pharmaceuticals, a clinical-stage c…

I would like to dedicate this episode to all the ROS developers. Now let’s go to the meat of the episode. Let me introduce you Limor Schweitzer. Limor is the CTO and founder of MOV.AI a company with the goal of infrastructure software for modern automation. His company has recently released the community edition of MOV. AI flow. Welcome to the podc…

I would like to dedicate this episode to all the developers working on building small robots for practice while studying ROS. There are very few ROS-based robots for students that are reliable. Now let’s go to the meat of the episode. Let me introduce you . Victor has a large career in building ROS-based companies. He was the founder of Erle Roboti…

I would like to dedicate this episode to the people that use ROS to develop autonomous robots that (will) move around us in our streets, together with us, humans, doing some useful tasks. Now let me introduce you Tomohiko Furutani. Tomohiko-san is the manager of the AI Robot development section of Softbank. Welcome to the podcast Tomohiko-san!…

I would like to dedicate this episode to people that are working to make robots more understandable by humans. People want people to interact seamlessly with robots. That robots understand us and that we understand robots. Now let me introduce you Severin Lemaignan. Severin is a senior scientist in social robotics at Pal Robotics. There he works to…

I would like to dedicate this episode to all the developers working on making efficient warehouse robots using ROS ( ROS-based warehouse robot). If you are in that field, if you are trying to make the picking system easier for all the warehouses around the world, then this episode is dedicated to you. Now let’s go to the meat of the episode. Let me…

Adrian is an advisor for several biotech companies in Argentina. Before joining CITES, a venture builder from Argentina, he worked as an advisor for RedCrow VC in San Francisco, and has more than 10 years working in the pharmaceutical industry in companies like Novartis and Merck KGaA. In this episode, we discuss his path from academia to big pharm…

I would like to dedicate this episode to the people that use other robotics frameworks different from ROS… and succeed. You know, ROS already provides you with a fully working robotics framework as well as many software for main robotics tasks. If you go outside ROS, the robotics world is cold, difficult, and hostile. If a company is able to succee…

I would like to dedicate this episode to all the developers working on using ROS for autonomous cars, then this episode is dedicated to you. Now let’s go to the meat of the episode. Let me introduce you Dr. Shimpei Kato. Shimpei is the founder of Tier IV as well as Chairman of the board of directors of the Autoware Foundation. Additionally, he is a…

Cyclacel Pharmaceuticals is a clinical-stage, biopharmaceutical company, developing innovative cancer medicines based on cell cycle, transcriptional regulation, and mitosis biology with a focus on oncology and hematology indications. Their lead drug candidate, fadraciclib is a dual CDK2/9 inhibitor currently undergoing investigation of dose escalat…

I would like to dedicate this episode to all the ROSDevelopers out there that have started or are already progressed doing progressing in programming robots by using FPGA and accelerating hardware of any kind. So if you are any of those engineers or ROSDevelopers using accelerate hardware for your robot, then this episode is dedicated to you! Now l…

I would like to dedicate this episode to the people that are developing space systems for the colonization of space, using ROS-based robots. If you are involved in this progress of humanity, this episode is dedicated to you. Now let me introduce you Alex Sowell and Misha Savchenko. Alex and Misha work on the Dexterous Robotics Team at NASA’s Johnso…

I would like to dedicate this episode to the people that are working to create ROS-based robots to do all the most tedious tasks like ironing, cleaning… or refilling the paper at the WC when finished. Now let me introduce you Dylan Terntzer the CEO and co-founder of Lionsbot. Welcome to the Podcast Dylan!…

I would like to dedicate this episode to all the ROSDevelopers out there that have started or are already progressed doing progressing in programming robots by using FPGA and accelerating hardware of any kind. So if you are any of those engineers or ROSDevelopers using accelerate hardware for your robot, then this episode is dedicated to you! Now l…

Radamés Cordero is the CEO of Melatech and an associate scientist and junior faculty in the department of Molecular Microbiology and Immunology at Johns Hopkins Bloomberg School of Public Health where he studies the biology of fungal melanin. As a spin-off of his research, Melatech is a biotech company dedicated to the production of melanin at indu…

I would like to dedicate this episode to the people that build and maintain the core of ROS, that is the people of Open Robotics. But specifically, this episode is dedicated to the Open Robotics team in Singapore that is heavily working on the development of Open-RMF, the new kid in town. Thank you very much to Matthew, Yadu, Aaron, and Luca. Thank…

Ratio Therapeutics is a Boston-based pharmaceutical company with the mission to accelerate the development of best-in-class targeted radiotherapeutics for the treatment of cancers. By employing a suite of innovative technologies the company is developing innovative and proprietary Pharmacokinetics (PK) Modulation technology for the construction of …

I would like to dedicate this episode to people that are attending the ROS CON. Now let me introduce you to Tomoya Fujita, Tomoya is a senior researcher of ROS and Cloud meeting software researcher at the SONY US Lab, where he works to develop ROS systems. Today he is going to explain everything about his project and his research development at the…

Dr. Anupam Chakravarty is a researcher whose research interests have straddled the disciplines of biochemistry and genomics with a keen focus on the biology of cancer. Currently, he is a senior scientist developing liquid biopsy assays and products in the precision oncology space at Guardant Health. Prior to joining Guardant Health, he ran his own …